ReviewPharmaceutics2021
Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed.
- Design Strategies for Developing Chiral Macrocyclic Chelators as a Diagnostic Tool.Accounts of chemical research · 2026Article
- Selective CXCR4-Targeting Radioconjugates Derived from LY2510924: Evaluation of [Pharmaceuticals (Basel, Switzerland) · 2026Article
- Chelator-Free Radiometal Labeling Inside Engineered Affibodies.Angewandte Chemie (International ed. in English) · 2026Article
- Complexes of DOTAM with dInorganic chemistry · 2026Article
- Radiolabeling efficiency of FENTA chelators and stability of their terbium-161, lutetium-177 and bismuth-213 complexes.EJNMMI radiopharmacy and chemistry · 2026Article
- Theranostic and Radionuclide-based Treatment Approaches for Radioiodine-refractory Thyroid Cancer: From Biology to Clinical Application.Molecular imaging and biology · 2026Review
- A Scoping Review of the Challenges and Future Perspectives in the Use of Alpha-Emitters for Metastatic Ovarian Cancer.Molecules (Basel, Switzerland) · 2026Article
- Bismuth Bicycles.Journal of peptide science : an official publication of the European Peptide Society · 2026Review
- Current and future perspectives on radioligand therapy in advanced prostate cancer.Therapeutic advances in medical oncology · 2026Review
- Chemical Tools to Characterize the Coordination Chemistry of Radionuclides for Radiopharmaceutical Applications.Chemical reviews · 2025Review
- Preclinical characterization of 3p-C-DEPAEJNMMI radiopharmacy and chemistry · 2025Article
- A Cursory Gaze at Solitary Radiopharmaceutical Chelators Incorporating Macrocyclic and Acyclic Moieties.Pharmaceutics · 2025Review
- Astatine-211-Labeled Therapy Targeting Amino Acid Transporters: Overcoming Drug Resistance in Non-Small Cell Lung Cancer.International journal of molecular sciences · 2025Review
- Clinical Experience with Targeted Alpha-Emitter Peptide Receptor Radionuclide Therapy (α-PRRT) for Somatostatin Receptor-Positive Neuroendocrine Tumors.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Review
- Review
- Radiotheranostic landscape: A review of clinical and preclinical development.European journal of nuclear medicine and molecular imaging · 2025Review
- Production and Supply of Raw Materials for Radiometals used in Radionuclide Imaging and Therapy in Korea.Nuclear medicine and molecular imaging · 2025Review
- The Advancement of Targeted Alpha Therapy and the Role of Click Chemistry Therein.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In contrast to external high energy photon or proton therapy, targeted radionuclide therapy (TRNT) is a systemic cancer treatment allowing targeted irradiation of a primary tumor and all its metastases, resulting in less collateral damage to normal tissues. The α-emitting radionuclide bismuth-213 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.